Please login to the form below

Not currently logged in

Industry welcomes UK’s £6bn science strategy

It will provide funding for projects including a big data collaboration and an ageing-focused innovation centre
UK flag

The UK has committed £6bn to support the growth of its science industry in a move welcomed by both the pharma and biotech industries.

The Science and Innovation Strategy, formally announced yesterday by universities, science and cities minister Greg Clark at the Royal Society, outlines key priorities to support science and innovation in the UK over the next six years.

It includes £3bn to support individual projects and to support existing laboratories at universities and research institutes. Half of this fund will be subject to competition to “ensure excellence is rewarded wherever it is found”, says the report.

A further £2.9bn will be available to fund large-scale science investments, including an initial investment of £800m.

This first wave of funding will be split among several projects including £235m for the creation of new facilities for advanced materials in Manchester, £113m to support a big data collaboration with IBM and £95m to enable the UK's leading role in the next European Rover mission to Mars.

Other prospects include an innovation centre on ageing in Newcastle and the extension of the capabilities of the National Nuclear Users Facility, a facility that gives access to experimental equipment for nuclear research on radioactive materials.

greg clark mpScience minister Clark (pictured right) said: “This strategy builds on the great strengths of British science and enterprise and will make sure the UK is the best place in the world to do science and grow an innovative business.

“This support to our scientific infrastructure means we will equal the best in the world.”

The investment was welcomed by industry bodies the Association of the British Pharmaceutical Industry (ABPI) and the BioIndustry Association (BIA).

Stephen Whitehead, CEO of the ABPI, had particular praise for the UK's promise to create two 'catapult' centres in energy systems and precision medicine next year.

"I hope that the strategy leads to a focus on sharpening the translational focus in academic discovery and bolstering its pull-through to commercially viable new therapies. This would help to underpin industry investment in the UK,” said Whitehead.

The BIA's CEO Steve Bates added: “In the Science and Innovation Strategy it's great to see a long-term government plan setting out capital commitments which take into account several recommendations the BIA made on behalf of its membership and the wider life sciences sector, such as the equitable split in funding for higher education and maintaining the UK's world class labs alongside large scale investments in major national and international projects.”

Article by
Thomas Meek

18th December 2014

From: Research, Healthcare



Subscribe to our email news alerts


Add my company
M3 (EU)

M3 has over 20 years’ experience in building online doctor communities. M3 is the world’s largest network of verified doctors...

Latest intelligence

Millennials: the wellness generation
Looking at the results from a global healthcare research study focusing on the patients of the future...
The problem with clinical trials (and how virtual insight-gathering can help)
While still the gold standard of research, clinical trials are often riddled with issues that limit their applicability to broader populations or delay market access....
The rise of digital healthcare – fuelled by open innovation in healthtech hubs
How the ever-increasing uptake of digital solutions is enhancing patient engagement, increasing access to care and lowering the cost of drug development...